Article

Mediastinal lymph node dissection for non-small cell lung cancer.

Journal of Thoracic and Cardiovascular Surgery (Impact Factor: 3.99). 09/2005; 130(2):241-2. DOI: 10.1016/j.jtcvs.2005.03.037
Source: PubMed

ABSTRACT The role of systematic mediastinal lymph node dissection in the staging and treatment of non-small cell lung cancer (NSCLC) is the subject of ongoing debate. Surgical practice varies from simple visual inspection of the unopened mediastinum to radical, systematic lymphadenectomy of all accessible lymph node levels. As the evaluation of mediastinal lymph nodes is a precondition for accurate intraoperative staging of NSCLC we advocate for complete interlobar, hilar and mediastinal lymphadenectomy as compartment dissections in patients with NSCLC. The therapeutic effect of extensive mediastinal lymphadenectomy, however, remains controversial. In this review we discuss the role of mediastinal lymph node dissection in the management of NSCLC.Copyright © 2010 S. Karger AG, Basel

0 Bookmarks
 · 
278 Views
  • [Show abstract] [Hide abstract]
    ABSTRACT: Oncologic surgery and pTNM staging require systemic removal of the locoregional lymphnodes. While the optimal extent and therapeutical and/or prognostic value of the lymphadenectomy/sampling are debated organ by organ and (sub)speciality by (sub)speciality, relevance of the lymphnode sytem-tumor concept itself is beyond doubt. Loss of information and existence of traps on the "surgical field-microscope" pathway is an international phenomenon, calling for solution. An integrated sterile and disposable lymphnode tray system is presented here for applications in the different fields of cancer surgery of the upper GI tract, retroperitoneum (gynecology, urology) and ear-nose-throat surgery.
    Magyar Sebészet (Hungarian Journal of Surgery) 02/2011; 64(1):6-11.
  • [Show abstract] [Hide abstract]
    ABSTRACT: The role of lymphadenectomy as an adjunct of standard excision for treatment of cancer is highly debated and controversial. Standard practice for treatment of solid tumors is resection with regional lymphadenectomy. This surgical concept assumes that cancers grow and spread in an orderly manner, from primary cancer to regional lymph nodes and finally to vital organs. We reviewed randomized trials, published a description of lymphatic anatomy and physiology, and presented data that disputed the role of lymphadenectomy as standard practice. The present review updates the literature and reiterates the concept that lymphadenectomy does not increase survival in the surgical treatment of solid tumors. We reviewed the English-language literature (Medline) for prospective randomized trials and nonrandomized reports, as well as retrospective studies addressing the role of lymphadenectomy in cancers of the esophagus, lung, stomach, pancreas, breast, and skin (melanoma) reported between 2000 and 2006. This extensive review demonstrates that there are few prospective randomized trials assessing patient survival with solid tumors that contrast resection with or without lymphadenectomy. However, there was at least one, and for some cancers more than one, prospective randomized trial for each organ site studied, and the data demonstrate no statistically significant difference in overall survival of patients treated with or without lymphadenectomy. Most nonrandomized and retrospective studies, with a few exceptions, support the conclusions of randomized trials; lymphadenectomy does not improve overall survival in solid tumors. Overall survival is primarily a function of the biological nature of the primary tumor, as evidenced by lymphovascular invasion, lymph node involvement, and other prognostic features. This extensive literature review of recent reports indicates that lymphadenectomy does not improve overall survival. Lymph node resection should be conceived in terms of staging, prognosis, and regional control only.
    Annals of Surgical Oncology 10/2007; 14(9):2443-62. · 3.94 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Stage I and II non–small cell lung cancer (NSCLC) should be resected, but there is mounting evidence for the use of preoperative induction and postoperative adjuvant therapy in stages IB and II, as being able to prolong life. Some patients in stage IIIA should undergo induction therapy, and then have re–staging of the mediastinum by CT/PET or redo mediastinoscopy before considering resection. Stages IIIB and IV are non–surgical, except very selected cases. Reflections are made regarding the control of cigarette smoking, the difficult access of patients from developing countries to the recent costly medical, pharmacological and technical advances; reflections are also made related to some ethical issues regarding medical and surgical treatment of NSCLC.
    Revista del Instituto Nacional de Enfermedades Respiratorias 06/2006; 19(2):143-147.

Full-text

Download
3 Downloads
Available from